Pyrazinyl Morpholine NR2B Modulators for Brain-Penetrant CNS Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing NR2B NMDA receptor modulators face challenges with psychotomimetic side effects, limited receptor pharmacology, and drug properties, while current compounds do not effectively target the NR2B subtype, necessitating the development of potent and selective NR2B negative allosteric modulators with improved brain penetration and metabolic stability.
Innovation Solution
Development of novel 4-pyrazin-2-ylmethyl-morpholines with a para-disubstituted pyrazinyl structure that act as potent and selective NR2B negative allosteric modulators, exhibiting high membrane permeability, no in vitro efflux, and metabolic stability in human liver microsomes, thereby enhancing brain penetration and duration of action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If non-selective NMDA receptor antagonists such as ketamine are used, then rapid onset of efficacy in MDD patients is achieved, but dissociative and psychogenic side effects occur
Solution Approach 1:
The patent applies local quality by targeting specifically the NR2B subtype of NMDA receptors rather than blocking all NMDA receptor subtypes non-selectively. This selective approach allows the compound to exert its antidepressant effect through NR2B modulation while avoiding the harmful dissociative and psychogenic side effects associated with non-selective NMDA antagonists like ketamine.
2Object-affected harmful factors
If NR2B NAM compounds are developed to reduce side effects, then dissociative and psychotomimetic side effects are diminished, but receptor pharmacology and other drug properties are limited
Solution Approach 1:
The patent employs parameter changes by systematically modifying molecular parameters of the NR2B NAM compounds, including introducing a para-disubstituted pyrazinyl structure, varying substituent groups (R1 and R2 positions), and adjusting physical-chemical properties such as membrane permeability and metabolic stability. These parameter optimizations enhance both the selective NR2B modulation activity and overall drug properties.
Solution Approach 2:
The patent applies composite materials by creating molecules with complex multi-functional structures that combine the NR2B selective modulation capability with improved pharmacokinetic properties. The compounds integrate multiple structural elements (morpholine core, pyrazinyl substituent, various R1 and R2 groups) to achieve both high receptor selectivity and favorable drug properties.
3Reliability
If compounds with high membrane permeability are designed to improve brain penetration, then brain penetration is enhanced, but metabolic stability may be compromised
Solution Approach 1:
The patent applies parameter changes by optimizing the balance between membrane permeability and metabolic stability through systematic variation of molecular parameters. The para-disubstituted pyrazinyl structure and specific substituent choices (R1 and R2 groups) are designed to simultaneously achieve high brain penetration via the blood-brain barrier while maintaining metabolic stability in human liver microsomes, as demonstrated by the compounds exhibiting both favorable permeability and stability profiles.
Data Source
AI summary
Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula Aand pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.